Brazilian: cost-cuts promise more cash for medical technology
This article was originally published in Clinica
Executive Summary
The significant savings that should result from a Brazilian initiative to rationalise the purchasing of high-cost medicines will be invested in increasing access to certain medical procedures and basic healthcare products. So said the health ministry of an e-tendering and price-referencing register for so-called "exceptional medicines", launched at the end of November. The programme is expected to halve the cost of some of these medicines, which make up a market worth R$1.2bn (US$540m).
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.